How to buy Effector Therapeutics (EFTR) shares in the UK

Learn how to easily invest in Effector Therapeutics shares.

Effector Therapeutics Inc (EFTR) is a publicly traded biotechnology business based in the US. In the week up to 13 September Effector Therapeutics shares surged 25.78% to a closing position of $0.6377. Over the last 12 months, Effector Therapeutics's share price has risen by 12.54% from $17.15. Effector Therapeutics is listed on the NASDAQ and employs 12 staff. All prices are listed in US Dollars.

How to buy shares in Effector Therapeutics

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: EFTR in this case.
  5. Research Effector Therapeutics shares. The platform should provide the latest information available.
  6. Buy your Effector Therapeutics shares. It's that simple.
The whole process can take as little as 15 minutes. You'll need a smartphone or computer, an internet connection, your passport or driving licence and a means of payment.

Fees for buying 50x Effector Therapeutics shares with popular platforms

Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.

Platform Platform fee Min. initial deposit Trading fee estimate
eToro Free Stocks logo £0 $10 £4.46
£896.22 total
Capital at risk
IG Share Dealing logo £0 £250 £13.75
£905.50 total
Capital at risk
Fineco logo £0 No minimum £8.92
£900.67 total
Capital at risk
Hargreaves Lansdown Fund and Share Account logo £0 £1 £20.87
£912.62 total
Capital at risk
Degiro Share Dealing logo £0 £0.01 £0.89
£892.65 total
Capital at risk
Freetrade logo £0 £1 £4.01
£895.77 total
Capital at risk
interactive investor Trading Account logo £9.99 per month No minimum £21.37
£913.12 total
Capital at risk
Stake logo £0 £50 £4.46
£896.22 total
Capital at risk
Halifax Share Dealing Account logo £36 per year £20 £20.65
£912.40 total
Capital at risk

Full comparison of share dealing platforms

Effector Therapeutics share price (NASDAQ:EFTR)

Use our graph to track the performance of EFTR stocks over time.

Effector Therapeutics price performance over time

Historical closes compared with the last close of $19.3

1 week (2022-09-20) 3,285.96%
1 month (2022-08-26) 2,982.57%
3 months (2022-06-27) 1,098.76%
6 months (2022-03-24) 315.05%
1 year (2021-09-27) 14.27%

Is it a good time to buy Effector Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Promoted
eToro Free Stocks

Invest in Effector Therapeutics shares with 0% commission

  • Start investing from as little as $10
  • Pay no stamp duty on UK shares
  • Join 25 million users who trust their investments with eToro
Other fees apply. Capital at risk

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is Effector Therapeutics under- or over-valued?

Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.

P/E ratio

Effector Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Effector Therapeutics shares trade at around 1x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Effector Therapeutics shares at a glance

Information last updated 2021-09-17.
Open$19.69
High$20.38
Low$18.2001
Close$19.3
Previous close$19.58
Change$-0.28
Change %-1.43%
Volume480,963
Information last updated 2022-09-23.
52-week range$0.47 - $17.99
50-day moving average$0.7225
200-day moving average$3.3244
Wall St. target price$9.68
PE ratio1.0225
Dividend yield$0 (0%)
Earnings per share (TTM)$0.55

Effector Therapeutics share dividends

We're not expecting Effector Therapeutics to pay a dividend over the next 12 months. Typically it's companies that have been around for longer that pay dividends (Effector Therapeutics had its IPO on 26 August 2021). However, you can browse other dividend-paying shares in our guide.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site